Epigenetic biomarkers in colorectal cancer diagnostics

References

• Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities. Nat. Rev. Gastroenterol. Hepatol.8(12), 711–722 (2011).
   PubMed Web of Science ®Google Scholar
• Crea F, Nobili S, Paolicchi E et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat.14(6), 280–296 (2011).
   PubMed Web of Science ®Google Scholar
• van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol.29(10), 1382–1391 (2011).
   PubMed Web of Science ®Google Scholar
• Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis28(12), 2434–2442 (2007).
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Goel A, Notohara K et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int. J. Cancer122(11), 2429–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol.8(12), 686–700 (2011).
   PubMed Web of Science ®Google Scholar
• Lynch HT, Lynch JF, Shaw TG. Hereditary gastrointestinal cancer syndromes. Gastrointest. Cancer Res.4(4 Suppl. 1), S9–S17 (2011).
   PubMedGoogle Scholar
• Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis.14(1), 3–17 (2012).
   PubMed Web of Science ®Google Scholar
• Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet.36(5), 497–501 (2004).
   PubMed Web of Science ®Google Scholar
• Chan TL, Yuen ST, Kong CK et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet.38(10), 1178–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Niessen RC, Hofstra RM, Westers H et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer48(8), 737–744 (2009).
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3´ exons of TACSTD1. Nat. Genet.41(1), 112–117 (2009).
   PubMed Web of Science ®Google Scholar
• Balaguer F, Moreira L, Lozano JJ et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res.17(19), 6239–6249 (2011).
   PubMed Web of Science ®Google Scholar
• Lanza G, Ferracin M, Gafa R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer6, 54 (2007).
   PubMed Web of Science ®Google Scholar
• Carmona FJ, Esteller M. Moving closer to a prognostic DNA methylation signature in colon cancer. Clin. Cancer Res.17(6), 1215–1217 (2011).
   PubMed Web of Science ®Google Scholar
• Lind GE, Danielsen SA, Ahlquist T et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol. Cancer10, 85 (2011).
   PubMed Web of Science ®Google Scholar
• Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst.97(15), 1124–1132 (2005).
   PubMed Web of Science ®Google Scholar
• Zou H, Harrington JJ, Shire AM et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol. Biomarkers Prev.16(12), 2686–2696 (2007).
   PubMed Web of Science ®Google Scholar
• Itzkowitz S, Brand R, Jandorf L et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol.103(11), 2862–2870 (2008).
   PubMed Web of Science ®Google Scholar
• Song BP, Jain S, Lin SY et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J. Mol. Diagn.14(2), 112–119 (2012).
   PubMed Web of Science ®Google Scholar
• Shirahata A, Sakuraba K, Goto T et al. Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. Anticancer Res.30(12), 5015–5018 (2010).
   PubMed Web of Science ®Google Scholar
• Luo YX, Chen DK, Song SX, Wang L, Wang JP. Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int. J. Clin. Pract.65(12), 1313–1320 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly D, Yang Z, Castaldi M et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res.13(4), R76 (2011).
   PubMed Web of Science ®Google Scholar
• Grutzmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One3(11), e3759 (2008).
   PubMed Web of Science ®Google Scholar
• de Vos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem.55(7), 1337–1346 (2009).
   PubMed Web of Science ®Google Scholar
• Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med.9, 133 (2011).
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol.10(3), 272–277 (2012).
   PubMed Web of Science ®Google Scholar
• He Q, Chen HY, Bai EQ et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet. Cytogenet.202(1), 1–10 (2010).
   PubMedGoogle Scholar
• Syed Sameer A, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum. Genomics5(5), 441–452 (2011).
   PubMedGoogle Scholar
• Yu J, Tao Q, Cheng YY et al. Promoter methylation of the Wnt/β-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer115(1), 49–60 (2009).
   PubMed Web of Science ®Google Scholar
• Rawson JB, Manno M, Mrkonjic M et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis32(5), 741–747 (2011).
   PubMed Web of Science ®Google Scholar
• Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J. Gastroenterol.12(44), 7113–7117 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet.36(4), 417–422 (2004).
   PubMed Web of Science ®Google Scholar
• Muller HM, Oberwalder M, Fiegl H et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet363(9417), 1283–1285 (2004).
   PubMed Web of Science ®Google Scholar
• Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol.13(6), 950–954 (2007).
   PubMed Web of Science ®Google Scholar
• Oberwalder M, Zitt M, Wontner C et al.SFRP2 methylation in fecal DNA – a marker for colorectal polyps. Int. J. Colorectal Dis.23(1), 15–19 (2008).
   PubMed Web of Science ®Google Scholar
• Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol.14(4), 524–531 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang W, Bauer M, Croner RS et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis. Colon Rectum50(10), 1618–1626; discussion 1626–1627 (2007).
   PubMed Web of Science ®Google Scholar
• Lee BB, Lee EJ, Jung EH et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res.15(19), 6185–6191 (2009).
   PubMed Web of Science ®Google Scholar
• Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol. Biomarkers Prev.20(7), 1272–1286 (2011).
   PubMed Web of Science ®Google Scholar
• Link A, Balaguer F, Shen Y et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev.19(7), 1766–1774 (2010).
   PubMed Web of Science ®Google Scholar
• Koga Y, Yasunaga M, Takahashi A et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res. (Phila.)3(11), 1435–1442 (2010).
   PubMed Web of Science ®Google Scholar
• Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut58(10), 1375–1381 (2009).
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer127(1), 118–126 (2010).
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res.18(10), 997–1006 (2008).
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Gruner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch.458(3), 313–322 (2011).
   PubMed Web of Science ®Google Scholar
• Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut57(7), 941–950 (2008).
   PubMed Web of Science ®Google Scholar
• de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J. Clin. Oncol.28(20), 3380–3387 (2010).
   PubMed Web of Science ®Google Scholar
• Shima K, Morikawa T, Baba Y et al.MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control22(2), 301–309 (2011).
   PubMed Web of Science ®Google Scholar
• Murakami J, Lee YJ, Kokeguchi S et al. Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol. Rep.17(6), 1461–1467 (2007).
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Sharp GB, Notohara K et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res.9(14), 5306–5312 (2003).
   PubMed Web of Science ®Google Scholar
• Nakajima TE, Yamada Y, Shimoda T et al. Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy. Eur. J. Cancer44(3), 400–407 (2008).
   PubMed Web of Science ®Google Scholar
• Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer117(14), 3156–3162 (2011).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J.11(1), 61–71 (2011).
   PubMed Web of Science ®Google Scholar
• Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol.11, 9 (2010).
   PubMed Web of Science ®Google Scholar
• Miyaki Y, Suzuki K, Koizumi K et al. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. Int. J. Oncol.40(1), 217–226 (2012).
   PubMed Web of Science ®Google Scholar
• Pancione M, Sabatino L, Fucci A et al. Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients’ outcome. PLoS One5(12), e14229 (2010).
   PubMed Web of Science ®Google Scholar
• Ebert MP, Tanzer M, Balluff B et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med.366(1), 44–53 (2012).
   PubMed Web of Science ®Google Scholar
• Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest.115(6), 1492–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int. J. Cancer121(3), 567–575 (2007).
   PubMed Web of Science ®Google Scholar
• Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-aza-2’deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer98(11), 1810–1819 (2008).
   Google Scholar
• Plummer R, Vidal L, Griffin M et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res.15(9), 3177–3183 (2009).
   PubMed Web of Science ®Google Scholar
• Shen L, Catalano PJ, Benson AB 3rd, O’Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res.13(20), 6093–6098 (2007).
   PubMed Web of Science ®Google Scholar
• Ogino S, Meyerhardt JA, Kawasaki T et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch.450(5), 529–537 (2007).
   PubMed Web of Science ®Google Scholar
• Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res.9(8), 2898–2903 (2003).
   PubMed Web of Science ®Google Scholar
• Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer117(9), 1847–1854 (2011).
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst.100(23), 1734–1738 (2008).
   PubMedGoogle Scholar
• Min BH, Bae JM, Lee EJ et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer11, 344 (2011).
   PubMed Web of Science ®Google Scholar
• Baba Y, Huttenhower C, Nosho K et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer9, 125 (2010).
   PubMed Web of Science ®Google Scholar
• Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci.102(1), 166–174 (2011).
   PubMed Web of Science ®Google Scholar
• Sunami E, de Maat M, Vu A, Turner RR, Hoon DS. LINE-1 hypomethylation during primary colon cancer progression. PLoS One6(4), e18884 (2011).
   PubMed Web of Science ®Google Scholar
• Schepeler T, Holm A, Halvey P et al. Attenuation of the β-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene doi:10.1038/onc.2011.453 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Chang KH, Miller N, Kheirelseid EA et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur. J. Surg. Oncol.37(7), 597–603 (2011).
   PubMed Web of Science ®Google Scholar
• Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology79(3–4), 313–320 (2010).
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA299(4), 425–436 (2008).
   PubMed Web of Science ®Google Scholar
• Valeri N, Gasparini P, Braconi C et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl Acad. Sci. USA107(49), 21098–21103 (2010).
   PubMed Web of Science ®Google Scholar
• Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res.68(15), 6416–6424 (2008).
   PubMed Web of Science ®Google Scholar
• Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA105(36), 13556–13561 (2008).
   PubMed Web of Science ®Google Scholar
• Kamimae S, Yamamoto E, Yamano HO et al. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. (Phila.)4(5), 674–683 (2011).
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res.14(6), 1669–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J. Gastroenterol.16(19), 2421–2427 (2010).
   PubMed Web of Science ®Google Scholar
• Fluge O, Gravdal K, Carlsen E et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br. J. Cancer101(8), 1282–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci.102(7), 1298–1305 (2011).
   PubMed Web of Science ®Google Scholar
• Lee CC, Chen WS, Chen CC et al. TCF12 protein functions as transcriptional repressor of E-cadherin, and its overexpression is correlated with metastasis of colorectal cancer. J. Biol. Chem.287(4), 2798–2809 (2012).
   PubMed Web of Science ®Google Scholar
• Crea F, Fornaro L, Paolicchi E et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol.23(5), 1207–1213 (2012).
   PubMed Web of Science ®Google Scholar
• Arai E, Kanai Y. DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics2(3), 467–481 (2010).
   PubMed Web of Science ®Google Scholar
• Kudo Y, Tateishi K, Yamamoto K et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci.103(4), 670–676 (2012).
   PubMed Web of Science ®Google Scholar
• Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis. Colon Rectum52(8), 1452–1459; discussion 1459–1463 (2009).
   PubMed Web of Science ®Google Scholar
• Jover R, Nguyen TP, Perez-Carbonell L et al. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology140(4), 1174–1181 (2011).
   PubMed Web of Science ®Google Scholar